NRCT Clinical Study in to Identify Acetaminophen-Induced Liver Injury Mechanism
Acetaminophen (APAP) (N-acetyl-p-aminophenol) is a chemical compound utilised in paracetamol treatments to reduce pain and lower fever. In June 2009, an FDA advisory group issued a warning concerning the potential of APAP overdose due to the drug’s side effects, which include drug-induced liver damage. In addition, the FDA has begun collecting data on APAP toxicity biomarkers in children and adolescents through multicenter non-interventional case-control studies. The National Center for Toxicological Research is a non-profit organisation that does toxicological research (NCTR), In partnership with various health institutes (hospitals, universities, and clinical centres) around the United States, the FDA coordinates the execution of APAP clinical trials. The purpose of these clinical trials is to collect enough data to build a list of biomarkers linked to acetaminophen toxicity that can be matched with specific adduct proteins; this information can then be used to investigate and predict future risks in children who are taking acetaminophen.
Author (S) Details
Department of Health Science, Walden University, Minneapolis, USA.
View Book :- https://stm.bookpi.org/IDHR-V3/article/view/3299
Acetaminophen biomarkers bleeding disorders Clinical trial coma drug-induced liver injury genomics integrated biologic kidney failure metabolomics non-toxic Paracetamol proteomics Technologies the food and drugs administration toxic